Also known as: LY3841136 · LY-3841136 · Elora
Updated 23 sources
Every Eloralintide protocol on file, 8 in all, labelled by where each number came from. 3 have titration steps, each step is worked out in U-100 units for a 10 mg vial + 1 mL water.
Who: 263 adults with BMI 30 or higher, or 27 or higher with a weight-related condition, without type 2 diabetes. Each arm stayed on one dose from day one.
Note: Weight change at 48 weeks: -9% (1 mg), -12% (3 mg), -18% (6 mg), -20% (9 mg) vs -0.4% on placebo (efficacy estimand). Starting at 6 mg brought the most nausea (64%).
Who: The 52-person escalation arm of the same phase 2 trial.
| When | Dose | U-100 units (10 mg vial + 1 mL water) |
|---|---|---|
| Weeks 1 to 4 | 3 mg | 30 units · 0.3 mL |
| Weeks 5 to 8 | 6 mg | 60 units · 0.6 mL |
| Weeks 9 to 48 | 9 mg | 90 units · 0.9 mL |
Note: Weight change -16% at 48 weeks. Nausea 25% and fatigue 21%, lower than the 6 to 9 mg arm (54% and 46%).
Who: The 24-person 6 to 9 mg arm of the same phase 2 trial.
| When | Dose | U-100 units (10 mg vial + 1 mL water) |
|---|---|---|
| Weeks 1 to 20 | 6 mg | 60 units · 0.6 mL |
| Weeks 21 to 48 | 9 mg | 90 units · 0.9 mL |
Note: Weight change -20% at 48 weeks, with nausea 54% and fatigue 46%.
Who: 100 adults with obesity or overweight in 5 cohorts, 12 weeks, at three US centres.
Note: Weight loss at week 12 ranged from 2.6% (1.2 mg) to 11.3% (12 mg). All three 12 mg participants with mood-related events stopped treatment; the events resolved in 2 to 4 days.
Who: 367 adults with obesity or overweight and type 2 diabetes in the US and Argentina. Arms also tested eloralintide with tirzepatide.
Note: Eloralintide alone: -8.2% (3 mg), -12.3% (6 mg), -11.1% (9 mg) vs -3.0% on placebo at 48 weeks. Topline press release, not yet peer reviewed.
Who: The combination arms of the same type 2 diabetes trial: eloralintide plus tirzepatide 5 to 15 mg as separate injections.
Timing: Started at eloralintide 1 or 3 mg with tirzepatide 2.5 mg, both escalated every 4 weeks to target.
Note: Eloralintide 9 mg plus tirzepatide 15 mg reached -23.3% vs -14.8% on tirzepatide 15 mg alone. Stopping for side effects was 10.8% to 27.0% on the combination vs 2.9% on tirzepatide alone.
Who: A dosing guide's ladder for research vials. The phase 2 trial did not run this exact schedule.
| When | Dose | U-100 units (10 mg vial + 1 mL water) |
|---|---|---|
| Weeks 1 to 4 | 1 mg | 10 units · 0.1 mL |
| Weeks 5 to 8 | 3 mg | 30 units · 0.3 mL |
| Weeks 9 to 12 | 6 mg | 60 units · 0.6 mL |
| Weeks 13 to 48 | 9 mg | 90 units · 0.9 mL |
Note: The closest trial arm went 3 to 6 to 9 mg in 4-week steps. No source sets a cycle length for research use.
Who: A calculator site's 'common' range for research vials. Below most trial arms.
Note: The site cites the phase 2 fixed-dose trial, but that trial's lowest dose was 1 mg and its doses ran to 9 mg. No trial tested 0.5 mg weekly.
Doses shown are what sources report, labelled by origin. Not medical advice.
| Water | Strength | 1 mgdose, units | 3 mgdose, units | 9 mgdose, units |
|---|---|---|---|---|
| 10 mg vial | ||||
| 1 mLCompetitor guide | 10 mg/mL | 100.1 mL | 300.3 mL | 900.9 mL |
| 2 mLCompetitor guide | 5 mg/mL | 200.2 mL | 600.6 mL | 1801.8 mL2 draws |
| 30 mg vial | ||||
| 3 mLCompetitor guide | 10 mg/mL | 100.1 mL | 300.3 mL | 900.9 mL |
Doses shown are what sources report, labelled by origin. Not medical advice.
Calculate with this peptideYour vial, your water, your dose: Eloralintide in syringe units, with the math shown.Diluent: Bacteriostatic water
Water volumes sources use: 1 mL, 2 mL, 3 mL
Trial publications do not describe mixing research powder. PeptideDosages calls its 1 mL preparation a worked calculation, not a trial formulation. Trial doses run to 9 mg, so a 10 mg vial holds about one high dose; plan water for an easy draw.
In the 48-week phase 2 trial, -9% at 1 mg, -12% at 3 mg, -18% at 6 mg and -20% at 9 mg, vs -0.4% on placebo. In people with type 2 diabetes, eloralintide alone reached -12.3% at 6 mg.
Phase 2 used 1, 3, 6 and 9 mg once weekly, plus two escalation arms (3 to 6 to 9 mg in 4-week steps, and 6 mg for 20 weeks then 9 mg). Phase 1 went up to 12 mg weekly for 12 weeks. No dose is approved.
In phase 2, people who started at 6 mg had 64% nausea. People who climbed 3 to 6 to 9 mg had 25%, while still losing 16% of their weight.
Dosing guides use 1 mL (10 mg/mL) or 2 mL (5 mg/mL). More water makes small doses easier to draw. The trials did not publish a mixing method for research powder.
9 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.
Back to the full Eloralintide page for side effects, storage, stacks and legal status.